Advanced in Methicillin-Resistant Staphylococcus Aureus (MRSA)

Dr. Olayemi O. Osiyemi

Infectious Disease
2580 Metrocentre Blvd, Suite 3, 
West Palm Bch, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Advanced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
2580 Metrocentre Blvd, Suite 3, 
West Palm Bch, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Olayemi Osiyemi is an Infectious Disease provider in West Palm Bch, Florida. Dr. Osiyemi is rated as an Advanced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are HIV/AIDS, Pneumonia, Hospital-Acquired Pneumonia, and Myelitis. Dr. Osiyemi is currently accepting new patients.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Internal Medicine in FL
Hospital Affiliations
St Mary's Medical Center
Jupiter Medical Center
Good Samaritan Medical Center
Languages Spoken
English
Spanish
Yoruba
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

TRIPLE O MEDICAL SERVICES PA
2580 Metrocentre Blvd, Suite 3, West Palm Bch, FL 33407

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States
Enrollment Status: Recruiting
Publish Date: August 11, 2025
Intervention Type: Other, Biological
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Long-acting cabotegravir, Long-acting rilpivirine, Rilpivirine, Dolutegravir
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease
Enrollment Status: Terminated
Publish Date: April 26, 2024
Intervention Type: Drug
Study Drugs: REGN14256, Imdevimab, Casirivimab+Imdevimab
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
Enrollment Status: Terminated
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: GSK3640254, Dolutegravir, Lamivudine
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Enrollment Status: Completed
Publish Date: March 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 10 Less Clinical Trials

31 Total Publications

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.
Journal: HIV medicine
Published: December 20, 2024
Similar Doctors
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Berjan A. Collin
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Berjan A. Collin
Infectious Disease

Associates In Infectious Diseases

356 E Midway Rd, 
Fort Pierce, FL 
 (44.9 miles away)
772-464-9746
Languages Spoken:
English, French, German, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Berjan Collin is an Infectious Disease provider in Fort Pierce, Florida. Dr. Collin is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Pneumonia, Osteomyelitis, Multisystem Inflammatory Syndrome in Children (MIS-C), and COVID-19. Dr. Collin is currently accepting new patients.

Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Mohamed Erritouni
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Mohamed Erritouni
Infectious Disease

Mohamed Erritouni MD Inc

5130 Linton Blvd, Suite G6, 
Delray Beach, FL 
 (22.1 miles away)
561-501-4266
Languages Spoken:
English, Arabic, Creoles And Pidgins, French
See accepted insurances
Accepting New Patients

Mohamed Erritouni is an Infectious Disease provider in Delray Beach, Florida. Dr. Erritouni is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Hospital-Acquired Pneumonia, Lymphangitis, Pneumonia, and Osteomyelitis. Dr. Erritouni is currently accepting new patients.

Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Christopher D. Cortes
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Christopher D. Cortes
Infectious Disease

Christopher D. Cortes, Md, Inc.

5352 Linton Blvd, 
Delray Beach, FL 
 (22.3 miles away)
561-498-4440
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Christopher Cortes is an Infectious Disease provider in Delray Beach, Florida. Dr. Cortes is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Lymphangitis, Hospital-Acquired Pneumonia, Pneumonia, and Osteomyelitis. Dr. Cortes is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Osiyemi's expertise for a condition
ConditionClose
View All 26 Advanced Conditions
View All 58 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile